Home  /  Resource Library  /  Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study

Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study

Results of a study indicates rituximab with bendamustine appears to be an effective salvage regimen for relapsed/refractory chronic lymphocytic leukemia.